The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma

Selcuk Erdem, Gulcin Yegen, Dilek Telci, Ibrahim Yildiz, Tzevat Tefik, Halim Issever, Isin Kilicaslan, Oner Sanli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: The aim of this study was to investigate the role of transglutaminase 2(TG2) in renal cell carcinoma (RCC) by comparing the immunohistochemistry staining of primary and metastatic tumor tissues. Methods: A total of 33 metastatic RCC(mRCC) and 33 non-metastatic RCC (nmRCC) patients who were matched as closely as possible based on gender, age, nuclear grade and pathologic T stage were retrospectively investigated. TG2 immunohistochemistry staining was performed on paraffin-embedded primary tumor tissues from both patient groups and on metastatic tissues from mRCC patients. The tissues were scored from 0 to 7 according to the TG2 staining. Furthermore, the patients were stratified into two groups using median primary tumor staining score as the cutoff value: Group 1 (high risk, n = 41) and Group 2(low risk, n = 22). The clinical, histopathological and survival outcomes were compared between these risk groups using Chi-square test, t test, Mann–Whitney U test and Kaplan–Meier survival analyses. Results: The median TG2 score for primary tumor was 5 for the entire study population. The median primary tumor TG2 score of the mRCC patients was significantly higher compared to the nmRCC patients (6 vs. 4, p < 0.001). The TG2 score between the primary and metastatic tissues of mRCC patients was not significantly different (6 vs. 7, p = 0.086). The percentage of metastatic patients was significantly higher in Group 1 compared to Group 2 (68.3 vs. 18.2 %, p < 0.001). Kaplan–Meier analyses showed that 5-year disease-free (34.9 vs. 92.9 %, p = 0.001) and cancer-specific (47.4 vs. 86.5 %, p = 0.04) survival rates were significantly lower in high-risk group. Conclusions: The increased expression of TG2 in primary tumor predicts metastasis in RCC patients and is also associated with a decrease in disease-free and cancer-specific survival outcomes.

Original languageEnglish (US)
Pages (from-to)1553-1560
Number of pages8
JournalWorld Journal of Urology
Volume33
Issue number10
DOIs
StatePublished - Oct 30 2015

Fingerprint

Renal Cell Carcinoma
Carcinogenesis
Neoplasm Metastasis
Survival
Neoplasms
Staining and Labeling
Immunohistochemistry
transglutaminase 2
Chi-Square Distribution
Survival Analysis
Paraffin
Survival Rate
Population

Keywords

  • Metastasis
  • Renal cell carcinoma
  • Transglutaminase 2
  • Tumor marker

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma. / Erdem, Selcuk; Yegen, Gulcin; Telci, Dilek; Yildiz, Ibrahim; Tefik, Tzevat; Issever, Halim; Kilicaslan, Isin; Sanli, Oner.

In: World Journal of Urology, Vol. 33, No. 10, 30.10.2015, p. 1553-1560.

Research output: Contribution to journalArticle

Erdem, Selcuk ; Yegen, Gulcin ; Telci, Dilek ; Yildiz, Ibrahim ; Tefik, Tzevat ; Issever, Halim ; Kilicaslan, Isin ; Sanli, Oner. / The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma. In: World Journal of Urology. 2015 ; Vol. 33, No. 10. pp. 1553-1560.
@article{fb00170dd6904c3180b27c77cf55417a,
title = "The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma",
abstract = "Purpose: The aim of this study was to investigate the role of transglutaminase 2(TG2) in renal cell carcinoma (RCC) by comparing the immunohistochemistry staining of primary and metastatic tumor tissues. Methods: A total of 33 metastatic RCC(mRCC) and 33 non-metastatic RCC (nmRCC) patients who were matched as closely as possible based on gender, age, nuclear grade and pathologic T stage were retrospectively investigated. TG2 immunohistochemistry staining was performed on paraffin-embedded primary tumor tissues from both patient groups and on metastatic tissues from mRCC patients. The tissues were scored from 0 to 7 according to the TG2 staining. Furthermore, the patients were stratified into two groups using median primary tumor staining score as the cutoff value: Group 1 (high risk, n = 41) and Group 2(low risk, n = 22). The clinical, histopathological and survival outcomes were compared between these risk groups using Chi-square test, t test, Mann–Whitney U test and Kaplan–Meier survival analyses. Results: The median TG2 score for primary tumor was 5 for the entire study population. The median primary tumor TG2 score of the mRCC patients was significantly higher compared to the nmRCC patients (6 vs. 4, p < 0.001). The TG2 score between the primary and metastatic tissues of mRCC patients was not significantly different (6 vs. 7, p = 0.086). The percentage of metastatic patients was significantly higher in Group 1 compared to Group 2 (68.3 vs. 18.2 {\%}, p < 0.001). Kaplan–Meier analyses showed that 5-year disease-free (34.9 vs. 92.9 {\%}, p = 0.001) and cancer-specific (47.4 vs. 86.5 {\%}, p = 0.04) survival rates were significantly lower in high-risk group. Conclusions: The increased expression of TG2 in primary tumor predicts metastasis in RCC patients and is also associated with a decrease in disease-free and cancer-specific survival outcomes.",
keywords = "Metastasis, Renal cell carcinoma, Transglutaminase 2, Tumor marker",
author = "Selcuk Erdem and Gulcin Yegen and Dilek Telci and Ibrahim Yildiz and Tzevat Tefik and Halim Issever and Isin Kilicaslan and Oner Sanli",
year = "2015",
month = "10",
day = "30",
doi = "10.1007/s00345-014-1462-7",
language = "English (US)",
volume = "33",
pages = "1553--1560",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma

AU - Erdem, Selcuk

AU - Yegen, Gulcin

AU - Telci, Dilek

AU - Yildiz, Ibrahim

AU - Tefik, Tzevat

AU - Issever, Halim

AU - Kilicaslan, Isin

AU - Sanli, Oner

PY - 2015/10/30

Y1 - 2015/10/30

N2 - Purpose: The aim of this study was to investigate the role of transglutaminase 2(TG2) in renal cell carcinoma (RCC) by comparing the immunohistochemistry staining of primary and metastatic tumor tissues. Methods: A total of 33 metastatic RCC(mRCC) and 33 non-metastatic RCC (nmRCC) patients who were matched as closely as possible based on gender, age, nuclear grade and pathologic T stage were retrospectively investigated. TG2 immunohistochemistry staining was performed on paraffin-embedded primary tumor tissues from both patient groups and on metastatic tissues from mRCC patients. The tissues were scored from 0 to 7 according to the TG2 staining. Furthermore, the patients were stratified into two groups using median primary tumor staining score as the cutoff value: Group 1 (high risk, n = 41) and Group 2(low risk, n = 22). The clinical, histopathological and survival outcomes were compared between these risk groups using Chi-square test, t test, Mann–Whitney U test and Kaplan–Meier survival analyses. Results: The median TG2 score for primary tumor was 5 for the entire study population. The median primary tumor TG2 score of the mRCC patients was significantly higher compared to the nmRCC patients (6 vs. 4, p < 0.001). The TG2 score between the primary and metastatic tissues of mRCC patients was not significantly different (6 vs. 7, p = 0.086). The percentage of metastatic patients was significantly higher in Group 1 compared to Group 2 (68.3 vs. 18.2 %, p < 0.001). Kaplan–Meier analyses showed that 5-year disease-free (34.9 vs. 92.9 %, p = 0.001) and cancer-specific (47.4 vs. 86.5 %, p = 0.04) survival rates were significantly lower in high-risk group. Conclusions: The increased expression of TG2 in primary tumor predicts metastasis in RCC patients and is also associated with a decrease in disease-free and cancer-specific survival outcomes.

AB - Purpose: The aim of this study was to investigate the role of transglutaminase 2(TG2) in renal cell carcinoma (RCC) by comparing the immunohistochemistry staining of primary and metastatic tumor tissues. Methods: A total of 33 metastatic RCC(mRCC) and 33 non-metastatic RCC (nmRCC) patients who were matched as closely as possible based on gender, age, nuclear grade and pathologic T stage were retrospectively investigated. TG2 immunohistochemistry staining was performed on paraffin-embedded primary tumor tissues from both patient groups and on metastatic tissues from mRCC patients. The tissues were scored from 0 to 7 according to the TG2 staining. Furthermore, the patients were stratified into two groups using median primary tumor staining score as the cutoff value: Group 1 (high risk, n = 41) and Group 2(low risk, n = 22). The clinical, histopathological and survival outcomes were compared between these risk groups using Chi-square test, t test, Mann–Whitney U test and Kaplan–Meier survival analyses. Results: The median TG2 score for primary tumor was 5 for the entire study population. The median primary tumor TG2 score of the mRCC patients was significantly higher compared to the nmRCC patients (6 vs. 4, p < 0.001). The TG2 score between the primary and metastatic tissues of mRCC patients was not significantly different (6 vs. 7, p = 0.086). The percentage of metastatic patients was significantly higher in Group 1 compared to Group 2 (68.3 vs. 18.2 %, p < 0.001). Kaplan–Meier analyses showed that 5-year disease-free (34.9 vs. 92.9 %, p = 0.001) and cancer-specific (47.4 vs. 86.5 %, p = 0.04) survival rates were significantly lower in high-risk group. Conclusions: The increased expression of TG2 in primary tumor predicts metastasis in RCC patients and is also associated with a decrease in disease-free and cancer-specific survival outcomes.

KW - Metastasis

KW - Renal cell carcinoma

KW - Transglutaminase 2

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=84942513609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942513609&partnerID=8YFLogxK

U2 - 10.1007/s00345-014-1462-7

DO - 10.1007/s00345-014-1462-7

M3 - Article

C2 - 25515319

AN - SCOPUS:84942513609

VL - 33

SP - 1553

EP - 1560

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 10

ER -